MDLZ.US Weekly Report · 2026-W30
MDLZ declined 0.79% this week, continuing consolidation ahead of earnings announcement. Although valuation sits at historical lows, it still trades above industry median. Institutional consensus remains constructive but capital shows broad net outflows. The upcoming Q2 earnings release will be the critical catalyst, with near-term direction likely determined by whether results justify the current premium valuation.
Market Performance
Closing at 60.52 compared to 61.00 on July 17, representing a 0.79% decline. Weekly range of 2.59% with intraweek high of 60.68 and low of 59.10, showing clear consolidation behavior.
Daily average trading volume around 8.11M shares aligns with the 60-day median range of 7-9M shares, showing no unusual concentration or thinning. Wednesday touched the week’s low of 59.86, followed by rebounds on Thursday and Friday, but failed to breach Monday’s opening of 60.04. Overall pattern reflects weak consolidation.
Valuation & Earnings
Current PE of 29.78 significantly exceeds the industry median of 8.30. However, based on 5-year history, valuations were lower only 12% of the time, indicating current multiples sit at relatively depressed levels historically. This reflects market recognition of premium positioning while introducing both upside potential and valuation risk.
Latest Q1 2026 report showed EPS of 0.4365, up 41.26% year-over-year, with revenue of $10.08B up 8.24%. Net profit growth of 39.3% outpaced revenue growth, indicating margin improvement. Current stock price at 60.52 aligns with TTM EPS of 2.03.
Consensus forecast for full-year EPS stands at 3.19, implying an annualized PE of 19x at current price. If Q1’s quarterly EPS of 0.44 were annualized, it would reach only 1.75, suggesting market anticipates significant acceleration in H2 earnings.
Capital Flows
As of July 24, all three investor categories show net outflows: large institutions -15.03M, medium institutions -6.49M, retail -11.01M. Simultaneous withdrawal by institutional and retail participants reflects either diminished market participation or cautious outlook, contrasting sharply with bullish analyst consensus.
Institutional Views
Among 24 analysts, 17 (71%) rate Buy/Strong Buy, 8 rate Hold, and none rate Sell. Consensus target of 67.27 implies 11.16% upside from current levels. Latest ratings updated July 24 show overall optimism, yet the divergence between constructive ratings and actual capital outflows suggests institutional views may lag market sentiment.
Takeaway
Two major contradictions emerge: PE of 29.78, though seemingly high in absolute terms, ranks at historical lows for the company with institutional backing and 11% upside embedded in target prices. Conversely, simultaneous institutional and retail outflows coupled with muted trading volume signal market hesitation. This split most likely reflects earnings anticipation—analysts remain optimistic pending confirmation while market participants adopt a wait-and-see stance ahead of Q2 results. A positive surprise could trigger stop-loss reversals and advance sharply; disappointing results risk further downside pressure.